{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-028724","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.786265+00:00","generated_at":"2026-06-05T08:54:12.275661+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera Q4 revenue up 43% to $311M; net loss narrows; guides 2024 rev $1.32-1.35B","bullets":["Q4 revenue $311.1M (+43.2% YoY); product revenue up 44.3% to $307.3M.","Net loss per share Q4 ($0.65) vs ($1.37) prior year; full year loss ($3.78) vs ($5.57).","Gross margin Q4 51.4% vs 41.4% YoY; full year 45.5% vs 44.4%.","Oncology tests Q4 up 52.3% to 97,500; FY up 73.5% to 340,700.","FY2024 guidance: revenue $1.32-1.35B; gross margin 50-53%; net cash consumption $50-75M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-028724","json":"https://secwatch.observer/filing/0001104659-24-028724.json","markdown":"https://secwatch.observer/filing/0001104659-24-028724.md","text":"https://secwatch.observer/filing/0001104659-24-028724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465924028724/0001104659-24-028724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465924028724/tm247042d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:54:12.275661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ac93e625a2b639b1802b6a7c6cef1c6945aab39","claim":"Natera, Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $311.1 million, net income ($0.65) per diluted share, EPS ($0.65) per diluted share.","evidence_excerpt":"testing , today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $311.1 million in the fourth quarter of 2023, compared to $217.3 million in the fourth quarter of 2022, an increase of 43.2%. Product revenues grew 44.3% over the same period. ● Generated total","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604821/000110465924028724/0001104659-24-028724-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$311.1 million"},{"label":"Net income","value":"($0.65) per diluted share"},{"label":"EPS","value":"($0.65) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}